

Product Update

adrenaline tartrate 150 and 300 microgram solution for injection in a pre-filled pen (Jext®) (No: 687/11) ALK-Abelló Ltd

01 February 2011 (Issued 09 September 2011)

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Adrenaline tartrate (Jext®) is accepted for use within NHS Scotland.

Indication under review: emergency treatment of severe acute allergic reactions (anaphylaxis) to insect stings or bites, foods, drugs and other allergens as well as idiopathic or exercise induced anaphylaxis.

For patients at risk of anaphylaxis and requiring adrenaline, this is a new presentation of adrenaline for emergency use. It has an extended shelf life (24 months) compared with some existing products.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 09 December 2010.

**Chairman,
Scottish Medicines Consortium**